A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

An Interventional, Open Label, Controlled, Randomized, Pairwise, Phase Ib Safety, Tolerability and Pharmacokinetic (PK) Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery

Open label controlled interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days.

Study Overview

• Status: Withdrawn
• Conditions: Cataract
• Intervention / Treatment: Drug: Levofloxacin Ocular Implant; Drug: Control

Detailed Description

This is a multicenter, open label, controlled, pairwise, interventional study in eyes in up to 12 subjects (24 eyes) scheduled for uncomplicated bilateral cataract surgery on separate days. Eligible individuals provide informed consent; and are screened for inclusion in the study.

Once eligible, subject eyes will be randomized to determine which eye will receive the first surgery. After the first surgery, study participants will receive the control treatment consisting of commercially available topical medications. For the second cataract surgery, study participants will receive a single Levofloxacin Ocular Implant in the posterior sulcus in the surgical eye at the end of cataract surgery. No sham dosing will be conducted in the eyes in the control arm.

• Study Type: Interventional
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Russell Tait; Phone Number: +61396570700; Email: russell.tait@polyactiva.com

Study Locations

• Australia
  • Victoria
    • Fitzroy, Victoria, Australia, 3065
      • Melbourne Eye Specialists
• United States
  • Missouri
    • Saint Louis, Missouri, United States, 63131
      • Ophthalmology Associates
  • South Carolina
    • Ladson, South Carolina, United States, 29456
      • Carolina Cataract and Laser Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria

1. Male or female subjects 18 years of age or older.
2. Willing and able to understand and sign an informed consent form prior to any study-related procedures.
3. Willing and able to follow study instructions, and able to be present for the required study visits/assessments for the duration of the study.
4. Diagnosis of cataract in both eyes scheduled for sequential bilateral elective cataract extraction by phacoemulsification and posterior chamber IOL implantation not combined with any other surgery except femtosecond laser.
5. Minimum endothelial cell density (ECD) in both eyes of greater than or equal to 2000 cells per mm2.
6. Fully vaccinated against COVID-19, as evidenced by vaccination record.

Key Opthalmic Exclusion Criteria

Ophthalmic:

1. Have a history of or current uveitis, macular edema (cystoid or diabetic), diabetic retinopathy, retinal vein occlusion and neovascular glaucoma, corneal conditions such as keratitis, corneal edema or advanced macular degeneration, which in the opinion of the investigator would interfere with study assessments and confound the data.
2. In the opinion of the investigator or reading center, have confluent central corneal guttatae, multiple central guttatae greater than a single cell, or corneal disease or abnormality that would prevent specular microscopy corneal scans.
3. Aphakia or low vision or monocular.
4. Have had any intraocular surgery, glaucoma surgery (including but not limited to filtering surgery like trabeculectomy, Ahmed valve, etc) or cornea/refractive surgery within the past 6 months or anticipate a need for eye surgery (including laser) during the study period.
5. Use of prostaglandin (PG) analogues within 60 days prior to Screening or during the course of the study.
6. Subjects with clinically diagnosed Fuchs' Endothelial Corneal Dystrophy (FECD)/ history of keratoplasty.
7. Subjects for whom an intra-ocular or glaucoma device procedure is planned during the cataract procedure, during study participation or has been previously undertaken.
8. Have a current retinal detachment or history of blunt trauma in either eye.
9. Subject who in the opinion of the surgeon has a high risk of the posterior capsule being compromised/zonular dehiscence during cataract surgery.
10. Intraoperative complications during the cataract surgery including posterior capsule rupture, zonular dehiscence, non-placement of Posterior Chamber Intra Ocular Lens (PCIOL), vitreous prolapse, lens fragments in the vitreous, placement of Anterior Chamber Intra Ocular Lens (ACIOL), uncontrolled bleeding /hyphema.
11. Known sensitivity to any component of the product (e.g. fluoroquinolone or polyurethane sensitivity), or to topical therapy used during course of study (e.g., povidone iodine, or anesthetics).
12. Used fluoroquinolone antibiotics (topically, orally or systemically) during the 4 weeks before screening visit.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Levofloxacin Ocular Implant; Biphasic levofloxacin antibiotic implant	Drug: Levofloxacin Ocular Implant; Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Active Comparator: Control; Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.	Drug: Control; Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of the Levofloxacin Ocular Implant	Descriptive summary statistics will be used to assess the number and frequency of ocular and non ocular adverse events	Day 90
Levofloxacin concentration in aqueous humor at Day 5 in treated eyes	To determine levofloxacin concentration in aqueous humor at Day 5 in eyes with the Levofloxacin Ocular Implant to facilitate dose adjustment for Phase II studies.	Day 5

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of actuations required to administer the implant	Clinicians administering the implant will record the number of actuations required to use the custom-built administration device	Day 0

Collaborators and Investigators

• Sponsor: PolyActiva Pty Ltd
• Investigators: Principal Investigator: Michael Coote, MD, Melbourne Eye Specialists

Study record dates

Study Major Dates

• Study Start (Estimated): June 23, 2023
• Primary Completion (Estimated): December 15, 2023
• Study Completion (Estimated): March 14, 2024

Study Registration Dates

• First Submitted: June 19, 2022
• First Submitted That Met QC Criteria: June 28, 2022
• First Posted (Actual): July 1, 2022

Study Record Updates

• Last Update Posted (Actual): April 12, 2024
• Last Update Submitted That Met QC Criteria: April 11, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Lens Diseases; Cataract; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Anti-Bacterial Agents; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Anti-Infective Agents, Urinary; Levofloxacin
• Other Study ID Numbers: LEVO-CS102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No